Cilengitide for subjects with newly diagnosed glioblastoma multiforme and methylated MGMT gene promoter – a multicenter, open-label, controlled Phase III study, testing cilengitide in combination with standard treatment (temozolomide with concomitant radi May 5, 2022 By Jesse Bufkin
A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration Resistant Prostate Cancer May 5, 2022 By Jesse Bufkin
This account was established to track IDS dispensing charges & SCCA adjusts to $0 in support of clinical research. May 5, 2022 By Jesse Bufkin
Bone Marrow Aspiration and Biopsy from Normal Individuals and Individuals with Cytopenias or Hematologic Disorders May 5, 2022 By Jesse Bufkin
Randomized Clinical Trial of the Safety and Efficacy of Brain Tissue Oxygen (pBrO2) Monitoring in the Management of Severe Traumatic Brain Injury May 5, 2022 By Jesse Bufkin
A PHASE II TRIAL OF GENOMIC GUIDED THERAPYWITH DASATINIB OR NILUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER May 5, 2022 By Jesse Bufkin
A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis May 5, 2022 By Jesse Bufkin
An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, andn Clinical Activity of the MEK Inhibitor GSK 1120212 in Subjects with Relapsed or Refractory Leukemias May 5, 2022 By Jesse Bufkin
